Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study

Clinical Nephrology

Volumn 64, Issue 2, 2005, Pages 113-123

  Provenzano, Robert ^a   Bhaduri, S ^b   Singh, A K ^c   Abrante, M ^d   Chang, D ^d   Lien, Y H ^d   Chandrashekar, J ^d   Dana, M ^d   Friedman, S ^d   Kleinman, K ^d   Kondle, V ^d   Lafayette, R A ^d   Madkour, H ^d   Makoff, D ^d   Mehta, R L ^d   Ricker, D ^d   Samson, M ^d   Shapiro, M ^d   Spira, M ^d   Sun, C ^d   Tucker, K ^d   Esson, M ^d   Caanthan, K D ^d   Cohen, J ^d   Geronemus, R ^d   Hoffman, D ^d   Locay, H ^d   McIvor, M ^d   Navarro, J ^d   Pellegrini, E ^d   Ramirez, G ^d   Rowe, D ^d   Serrano, G ^d   Vacker, M ^d   Weiss, R ^d   Zeig, S ^d   Bazemore, J ^d   Frederickson, E ^d   Himot, E ^d   Martinez, C ^d   Murphy, S ^d   Nass, K ^d   Obialo, C ^d   Vainer, S ^d   Bilinsky, R ^d   Ghossein, C ^d   Kamran, M ^d   Leehey, D J ^d   Sparrow, R ^d   Karp, S L ^d   Taber, T ^d   Kaskas, M ^d   Zabaneh, R ^d   Hood, S ^d   Kershaw, G ^d   Lazowski, P ^d   Shih, D ^d   Slater, J ^d   Al Talib, K K ^d   Fink, J ^d   Turer, P ^d   Wassem, M ^d   Al Saghir, F ^d   Rao, V ^d   Awad, A ^d   Domoto, D ^d   Mellas, J ^d   Brandspigel, K ^d   Spry, L ^d   Eidelson, B ^d   Feldman, J ^d   Haratz, A ^d   Huq, M ^d   Lehrner, L ^d   Leisrowitz, M ^d   Shete, L ^d   Henriquez, M ^d   Hoy, C ^d   Mailloux, L ^d   Miller, I J ^d   Parnes, E ^d   Scott, D ^d   Wagner, J ^d   Cohen, L H ^d   Dennis, V W ^d   Kant, K S ^d   Malhotra, D K ^d   von Hartitzsch, B ^d   Kennefick, T M ^d   Benz, R L ^d   Clark, E ^d   Filippone, E ^d   Foti, F ^d   Kurtzer, Y B ^d   Levenson, D ^d   Raza, H ^d   Rodenberger, C ^d   Rudnick, M ^d   Testa, M A ^d   more..

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b Ortho Biotech Products LP   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

Anemia; Chronic kidney disease; Epoetin alfa; Hemoglobin

Indexed keywords

CREATININE; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTICENTER STUDY; PERIPHERAL EDEMA; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 23144460027     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64113     Document Type: Article

References (34)

1. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ 2001 Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955-962
2. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients 1992 Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61: 399-403
3. Bárány P, Pettersson E, Konarski-Svensson JK 1993 Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 8: 426-432
4. Caro J, Brown S, Miller O, Murray T, Erslev AJ 1979 Erythropoietin levels in uremic: nephric and anephric patients. J Lab Clin Med 93: 449-458
5. Collins A, Li S, St. Peter W, Ebben J, Roberts T, Ma JZ, Manning W 2001 Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473
6. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the PROCRIT Study Group 1998 Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-3425
7. Egrie JC, Browne JK 2001 Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Suppl 3): 3-13
8. Eschbach JW 1989 The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148
9. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE 1996 The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61
10. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M 2005 Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant (Epub ahead of print http://ndt.oxfordjournals.org/cgi/reprint/gfh919vl)
11. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group 1997 Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234
12. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC 2004 Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int Aug; 66: 753-760
13. Hsu CY, McCulloch CE, Curhan GC 2002 Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504-510
14. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK 2001 Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16: 307-312
15. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P 2002 Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 17: 1621-1627
16. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O 1997 Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185
17. Laupacis A, Wong C, Churchill D 1991 The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Contr Clin Trials 12 (4 Suppl): 168S-179S
18. Laupacis A, Muirhead N, Keown P, Wong C 1992 A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 60: 302-306. Erratum in Nephron 61: 248
19. Levey AS, Bosch JP, Lewis JR, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470
20. Lopez-Gomez JM 2000 Effects of partial correction of anemia on left ventricular structure and function. Proc Am Soc Nephrol 33rd annual meeting.
21. Ma JZ, Ebben J, Xia H, Collins AJ 1999 Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619
22. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J 1999 Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395
23. McClellan W, Aronoff S, Bolton W, Hood S, Lorber D, Tang KL, Tse T, Wasserman B, Leiserowitz M 2004 The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20: 1501-1510
24. Mohanram A, Zhang Z, Shahinfar S, Keane WD, Brenner BM, Toto RD 2004 Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66: 1131-1138
25. National Kidney Foundation 2001 K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37(Suppl 1): S182-S238
26. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J 1991 Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 35: 280-287
27. Petroff S, Germain M, O'Shea M, Mulhern J, Braden G, Sweet S, Poppel D 2001 Prolonged erythropoietin (EPO) dosing intervals in pre-ESRD patients. J Am Soc Nephrol 12: 407A [abstr A2098 and poster]
28. Provenzano R, Garcia-Mayol L, Suchinda P, von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC, and the POWER Study Group 2004 Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61: 392-405
29. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A 2000 The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737-1744
30. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A 2003 The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141-146
31. The US Recombinant Human Erythropoietin Predialysis Study Group 1991 Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18: 50-59
32. Valderábano F, Jofre R, López-Gómez JM 2001 Quality of life in end-stage renal disease patients. Am J Kidney Dis 38: 443-464
33. Zappacosta AR, Perras ST, Bell A 1991 Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med 91: 229-232
34. Zehnder C, Zuber M, Sulzer M, Meyer B, Straumann E, Jenzer HR, Blumberg A 1992 Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 61: 21-25